Houston, TXNCT06458712Now EnrollingIRB Ready

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases) Clinical Trial in Houston, TX

Access cutting-edge advanced malignancies with homologous recombination deficiency (hrd) (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain metastases) treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by Duke Street Bio Ltd

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access advanced malignancies with homologous recombination deficiency (hrd) (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain metastases) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced malignancies with homologous recombination deficiency (hrd) (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain metastases) treatment provided free

Apply for This Houston Location

Check if you qualify for this advanced malignancies with homologous recombination deficiency (hrd) (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain metastases) clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases) Study in Houston

Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.

Sponsor: Duke Street Bio Ltd

Who Can Participate

Inclusion Criteria

The participant (or legally acceptable representative, if applicable) provides written informed consent for the study.
Aged ≥18 years of age on the day of signing the informed consent.
Has measurable disease per RECIST v1.1, or non-measurable disease as defined in the protocol.
ECOG performance status of 0 to 1.
Life expectancy \>12 weeks.
Adequate organ function as defined in the protocol.
Willing and able to comply with scheduled visits (including follow-up visits), and protocol procedures.
Willing and able to undergo imaging procedures as per protocol.
Willing to provide blood samples for correlative research purposes.
Able to swallow oral medication as an intact dosage form.
Prior intervention with an approved non-selective PARP inhibitor is permitted in Dose Escalation only.
Histologically confirmed diagnosis of locally advanced and/or metastatic breast cancer, prostate cancer, ovarian cancer, or pancreatic ductal adenocarcinoma with confirmed gene alterations as defined in the protocol.
Has received prior cancer treatment as outlined in the protocol, dependent on disease type.
Known asymptomatic or symptomatic brain metastasis, as confirmed by an MRI brain scan, from a primary tumour and meeting the eligibility for the disease types noted above (Dose Expansion only).

Exclusion Criteria

Myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) or features suggestive of MDS/AML.
Has received a prior PARP1-selective inhibitor.
Has received prior systemic anti-cancer therapy including investigational agents or device within 2 or 4 weeks prior to study intervention, dependent on the treatment.
Received prior radiotherapy within 2 weeks of the start of study intervention or has a history of radiation pneumonitis.
Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: administration of killed vaccines are allowed.
Has had an allogeneic tissue/solid organ transplant.
Has an active autoimmune disease that has required systemic intervention in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
Refractory nausea and vomiting, impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs.
Undergone major surgery, open biopsy or significant traumatic injury ≤28 days prior to starting study intervention.
Has an active infection requiring systemic therapy or an uncontrolled concurrent illness.
Known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by the local health authority.
Known history of Hepatitis B or known active Hepatitis C virus (HCV)
Cirrhosis of the liver.
Clinically significant pulmonary illness.
Impaired cardiac function or clinically significant cardiac disease.
Participants with a healing, serious or open wound, ulcer, or bone fracture within 28 days prior to first dose of study intervention.
History or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participants involvement for the full duration of the study.
A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to starting the study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
Weight loss of \>5% in the 8-week period prior to starting study intervention.
Known allergy or hypersensitivity to any of the formulation components of DSB2455.
Has received radiation therapy to the lung that is \>30Gy within 6 months of the first dose of study intervention.
Other disease-specific criteria as outlined in the protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT06458712) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases) Treatment Options in Houston, TX

If you're searching for advanced malignancies with homologous recombination deficiency (hrd) (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain metastases) treatment options in Houston, TX, this clinical trial (NCT06458712) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced malignancies with homologous recombination deficiency (hrd) (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain metastases) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced malignancies with homologous recombination deficiency (hrd) (breast, ovarian, mcrpc, pancreatic ductal adenocarcinoma (pdac), brain metastases) clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in Houston, TX

See all pancreatic cancer clinical trials recruiting in Houston — not just this study.

Browse Pancreatic Cancer Trials in Houston →

Browse More Trials by Condition

Pancreatic Cancer TrialsBrain Cancer TrialsAlzheimers Disease TrialsParkinsons Disease TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsUlcerative Colitis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX